UK clinical trials of a new potential drug treatment for uveitis

15 January 15

written by:

Ade Deane-Pratt

(more articles)

A pharmaceutical company is currently running two clinical trials to study a potential new drug treatment for non-infectious uveitis. The research team is looking for eligible people to take part.

Uveitis is the general name for inflammation in the eye’s middle layer (the uvea). It is one of the leading causes of blindness. While uveitis may be caused by infection or injury it is more likely to be the result of conditions in which the body’s defences against infection (the immune system) do not work properly.

Is it safe and does it work?

Gevokizumab is the name of a new drug that works on a specific part of the immune system and may help to improve the symptoms of non-infectious uveitis. The drug has not yet been approved for use in the clinic in the UK or abroad. Before that can happen it needs to be tested in a series of clinical trials to find out about what dose to give people, whether it is safe and whether it works.

For more information about the trials, go to